Hims & Hers (HIMS) faces downside risk as its GLP1 business shifts from high-margin compounding to low-margin distribution of Novo Nordisk brand, causing margin compression and likely guidance cuts; the stock's multiple has already expanded, but earnings estimates have not been reset.